JP2014534265A5 - - Google Patents

Download PDF

Info

Publication number
JP2014534265A5
JP2014534265A5 JP2014543618A JP2014543618A JP2014534265A5 JP 2014534265 A5 JP2014534265 A5 JP 2014534265A5 JP 2014543618 A JP2014543618 A JP 2014543618A JP 2014543618 A JP2014543618 A JP 2014543618A JP 2014534265 A5 JP2014534265 A5 JP 2014534265A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
seq
amino acid
acid sequence
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014543618A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014534265A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/066795 external-priority patent/WO2013082116A1/en
Publication of JP2014534265A publication Critical patent/JP2014534265A/ja
Publication of JP2014534265A5 publication Critical patent/JP2014534265A5/ja
Pending legal-status Critical Current

Links

JP2014543618A 2011-11-28 2012-11-28 インスリンアミノ酸配列を含む治療薬 Pending JP2014534265A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161563985P 2011-11-28 2011-11-28
US61/563,985 2011-11-28
PCT/US2012/066795 WO2013082116A1 (en) 2011-11-28 2012-11-28 Therapeutic agents comprising insulin amino acid sequences

Publications (2)

Publication Number Publication Date
JP2014534265A JP2014534265A (ja) 2014-12-18
JP2014534265A5 true JP2014534265A5 (https=) 2016-01-21

Family

ID=48536000

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014543618A Pending JP2014534265A (ja) 2011-11-28 2012-11-28 インスリンアミノ酸配列を含む治療薬

Country Status (14)

Country Link
US (2) US20130150291A1 (https=)
EP (1) EP2785367A4 (https=)
JP (1) JP2014534265A (https=)
KR (1) KR20140103985A (https=)
CN (1) CN104080473A (https=)
AU (1) AU2012346058A1 (https=)
BR (1) BR112014012789A2 (https=)
CA (1) CA2856967A1 (https=)
HK (1) HK1202067A1 (https=)
IL (1) IL232781A0 (https=)
MX (1) MX2014006391A (https=)
RU (1) RU2014126244A (https=)
SG (1) SG11201402661TA (https=)
WO (1) WO2013082116A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
EP3412300A1 (en) 2008-06-27 2018-12-12 Duke University Therapeutic agents comprising elastin-like peptides
WO2012170524A1 (en) 2011-06-06 2012-12-13 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
WO2014081849A1 (en) 2012-11-20 2014-05-30 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
JP2016505627A (ja) * 2013-01-15 2016-02-25 フェーズバイオ ファーマシューティカルズ,インコーポレイテッド 治療剤、組成物、および血糖コントロールのための方法
WO2015172046A1 (en) 2014-05-08 2015-11-12 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
EP3147369B1 (en) * 2014-05-21 2025-08-06 Ajinomoto Co., Inc. Fibroin-like protein production method
JP7075757B2 (ja) * 2014-11-21 2022-05-26 フェーズバイオ ファーマシューティカルズ,インコーポレイテッド 制御放出および持続的放出のためのelp融合タンパク質
CA2976038A1 (en) 2015-02-09 2016-08-18 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
EP3124495A1 (en) * 2015-07-31 2017-02-01 Centre National de la Recherche Scientifique (C.N.R.S.) Derivatives of elastin-like polypeptides and uses thereof
JP6882782B2 (ja) 2015-08-04 2021-06-02 デューク ユニバーシティ 遺伝子コードされた本質的に無秩序な送達用ステルスポリマーおよびその使用方法
CN105061566A (zh) * 2015-09-05 2015-11-18 苏州普罗达生物科技有限公司 拟胰岛素多肽及其应用
WO2017052305A1 (en) * 2015-09-24 2017-03-30 Hanmi Pharm. Co., Ltd. Method of insulin production
KR101815080B1 (ko) 2015-11-03 2018-01-04 재단법인대구경북과학기술원 췌장소도세포 및 엘라스틴 유사 인공 세포외 기질을 포함하는 당뇨병 치료용 약학적 조성물
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
MX395130B (es) 2016-03-02 2025-03-24 Merz Pharma Gmbh & Co Kgaa Composicion que comprende toxina botulinica
WO2017189860A1 (en) 2016-04-27 2017-11-02 The Regents Of The University Of California Preparation of functional homocysteine residues in polypeptides and peptides
ES2909074T3 (es) * 2016-05-06 2022-05-05 Phasebio Pharmaceuticals Inc Proteínas de fusión ELP para liberación controlada y sostenida
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
EP3515928B1 (en) 2016-09-23 2026-01-28 Duke University Unstructured non-repetitive polypeptides having lcst behavior
US11220467B2 (en) 2017-01-11 2022-01-11 Recycle Track Systems, Inc. Indoor food waste fermentation and recycling process
WO2018132732A1 (en) 2017-01-12 2018-07-19 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
WO2018233813A1 (en) 2017-06-20 2018-12-27 Merz Pharma Gmbh & Co. Kgaa Novel recombinant botulinum toxin with increased duration of effect
WO2019006374A1 (en) 2017-06-30 2019-01-03 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS
ES2930237T3 (es) 2017-07-06 2022-12-09 Merz Pharma Gmbh & Co Kgaa Neurotoxinas botulínicas recombinantes nuevas con mayor duración de efectos
US12296018B2 (en) 2018-01-26 2025-05-13 Duke University Albumin binding peptide-drug (AlBiPeD) conjugates and methods of making and using same
EP3788343B1 (en) 2018-04-30 2024-03-27 Duke University Stimuli-responsive peg-like polymer-based drug delivery platform
EP3829622A4 (en) 2018-08-02 2022-05-11 Duke University DOUBLE AGONIST FUSION PROTEINS
WO2020051541A1 (en) 2018-09-07 2020-03-12 Duke University Nanoparticulate drug delivery systems
KR102456958B1 (ko) * 2019-05-14 2022-10-21 강원대학교 산학협력단 당뇨병성 합병증의 예방 또는 치료용 약제학적 조성물
CN111939244B (zh) 2019-05-14 2024-08-06 阿莫生命科学有限公司 用于预防或治疗糖尿病并发症的药物组合物
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
US12435116B2 (en) 2019-10-16 2025-10-07 Clarence Hurt Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome
KR20220110556A (ko) * 2019-12-06 2022-08-08 아지노모토 가부시키가이샤 생리 활성을 갖는 펩타이드의 제조 방법 및 단쇄 링커를 포함하는 펩타이드

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2309955A1 (en) * 1997-11-12 1999-05-20 Alza Corporation Method for decreasing self-association of polypeptides
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
CN101384272B (zh) * 2005-12-20 2013-05-01 杜克大学 用于递送具有增强的药理性质的活性剂的方法和组合物
AU2007215012A1 (en) * 2006-02-15 2007-08-23 Imclone Llc Antibody formulation
CN101616685B (zh) * 2006-03-06 2013-07-24 阿穆尼克斯运营公司 非结构化重组聚合物和其应用
EP3412300A1 (en) * 2008-06-27 2018-12-12 Duke University Therapeutic agents comprising elastin-like peptides
WO2010014689A1 (en) * 2008-07-29 2010-02-04 Phasebio Pharmaceuticals, Inc. Pharmaceutical formulations comprising elastin-like proteins
PL2459171T3 (pl) * 2009-07-31 2017-11-30 Sanofi-Aventis Deutschland Gmbh Kompozycja insuliny o długim działaniu
DK3311828T3 (da) * 2009-08-14 2021-06-28 Phasebio Pharmaceuticals Inc Modificerede vasoaktive tarmpeptider

Similar Documents

Publication Publication Date Title
JP2014534265A5 (https=)
RU2014126244A (ru) Лекарственные средства, содержащие аминокислотные последовательности инсулина
JP2010031018A5 (https=)
JP6084215B2 (ja) ポリエチレングリコールまたはその誘導体でpeg化されたエキセンジン−4類似体、その調製法、および活性成分としてこれを含有する、糖尿病を予防または処置するための薬学的組成物
RU2434640C2 (ru) Лечение метастатического рака молочной железы
CA2729938A1 (en) New insulin analogues of prolonged activity
ES2614287T3 (es) Lixisenatida como terapia adicional a la insulina basal en diabetes de tipo 2
ES2953631T3 (es) Agonistas del receptor de GLP-1/glucagón en el tratamiento de la enfermedad de la esteatosis hepática y la esteatohepatitis
CN102718858A (zh) 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
CN102643339B (zh) 一种glp-1类似物、制备方法及其应用
JP2021521230A5 (https=)
ES2723887T3 (es) Formulación de relación fija de insulina glargina/lixisenatida
MY158627A (en) Halogen-stabilized insulin
HRP20150353T1 (hr) Farmaceutski pripravak koji sadrži glp-1 agonist, inzulin i metionin
JP2016516076A5 (https=)
JP2014526441A5 (https=)
UA95488C2 (ru) Концентрированный раствор метотрексата для подкожного введения
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
JP2019517542A5 (https=)
ES2971959T3 (es) Terlipresina para el tratamiento de la ascitis debida a cirrosis hepática administrada como una infusión continua
JP2017529326A5 (https=)
CN103665148A (zh) 一种可口服给药的降糖多肽及其制法和用途
JP2019527053A5 (https=)
JP2020533302A (ja) 肥満の治療において使用するためのmic−1およびglp−1
PT2285416E (pt) Conjugados para o tratamento de mesotelioma